ISEE Jan 2025 2.500 call
| Previous Close | 35.00 |
| Open | 35.00 |
| Bid | 34.10 |
| Ask | 39.00 |
| Strike | 2.50 |
| Expire Date | 2025-01-17 |
| Day's Range | 35.00 - 35.00 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 4 |
Business WireIveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PARSIPPANY, N.J., July 05, 2023--Iveric Bio granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 23 newly-hired, non-executive employees.
ZacksAnnexon (ANNX) Stock Down More Than 50% Last Week: Here's Why
Annexon (ANNX) announces mixed top-line results from the phase II study of ANX007 in patients with geographic atrophy.
- Reuters
UPDATE 1-Japan's Astellas Pharma agrees to buy IVERIC Bio for $5.9 bln
Japan's Astellas Pharma said on Monday it agreed to buy U.S.-based drugmaker IVERIC Bio Inc for about $5.9 billion in its biggest acquisition, giving it access to a range of ophthalmology treatments. Through Berry Merger Sub Inc, a wholly-owned subsidiary of Astellas U.S. Holding, the Japanese company agreed to acquire IVERIC for $40 per share in cash, Astellas said in a release. The acquisition price is a 22% premium to IVERIC's $32.89 closing price on April 28.
